McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
VALENCIA, Calif., Jan. 03, 2017 -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today confirmed that following the completion of initial formulation studies it received a $1 million milestone payment from Receptor Life Sciences, Inc. (RLS) on Friday, December 30, 2016. This milestone payment is part of a previously announced collaboration and license agreement between the company and RLS.
Matthew J. Pfeffer, Chief Executive Officer of MannKind, commented, “The results of these studies have further validated the versatility of our formulation technology. We are pleased with the progress to date and look forward to the next phase of product development in our collaboration with RLS.”
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
About Receptor Life Sciences, Inc.
Receptor Life Sciences, Inc. is a pharmaceutical development company based in Seattle, Washington. Receptor is quietly laying the foundation for groundbreaking new products in the specialty pharmaceutical market.
Company Contact: Rose Alinaya SVP Finance 661-775-5300 [email protected]
